急性缺血性脑血管病(ICVD),为临床常见病,急性期治疗是否恰当对预后影响很大,中重度进展性卒中疗效不佳,致残率较高.目前治疗方法繁多,疗效差别很大,且无规范方案.东菱精纯克栓酶(DF521)是一种新型强力溶栓,改善微循环治疗剂,文献报导该药疗效可靠,有效率达80%~90%我们自1995年开始应用该药治疗急慢性ICVD患者现就 Acute ischemic cerebrovascular disease (ICVD), is a common clinical disease, the acute phase of the treatment is appropriate for the prognosis of a great effect in the treatment of moderate and severe poor performance, high morbidity. Currently the treatment of many, the effect is very different Large, and no normative program.Dangling fine Keke thrombin (DF521) is a new type of powerful thrombolytic therapy to improve microcirculation, reported in the literature of the curative effect is reliable, the efficiency of 80% to 90% since 1995 The application of the drug began to treat patients with acute and chronic ICVD